BiotechTube
IFM Therapeutics (2)

IFM Therapeutics (2)

United States· Est.
ifmthera.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $86.5M

Overview

IFM Therapeutics is a pioneering biotech focused on modulating the innate immune system through first-in-class small molecules. It has demonstrated an exceptional track record of rapidly advancing programs from discovery to the clinic and securing major pharmaceutical partnerships and acquisitions, including multi-billion dollar deals with Bristol Myers Squibb and Novartis. The company's current lead asset, DFV890 (formerly IFM-2427), is a NLRP3 antagonist in multiple Phase 2 trials across inflammatory and hematologic indications. Its innovative 'IFM Model' of subsidiary creation allows for focused R&D and capital-efficient value realization.

OncologyInflammatory Diseases

Technology Platform

Small molecule drug discovery platform targeting key control nodes of the innate immune system, specifically the NLRP3 inflammasome and cGAS-STING pathways, with capabilities to develop both agonists and antagonists.

Funding History

2
Total raised:$86.5M
Series B$55.5M
Series A$31M

Opportunities

The innate immune system represents a vast, relatively untapped frontier for drug discovery in both inflammation and oncology.
Successful clinical development of DFV890 could address massive markets like osteoarthritis and cardiovascular disease.
The company's proven subsidiary model enables efficient capital deployment and high-value exits, positioning it to continuously pioneer new targets.

Risk Factors

Clinical failure of the lead NLRP3 antagonist DFV890 in ongoing Phase 2 trials is a key pipeline risk.
Competition in the innate immunity space is rapidly increasing from other biotechs and large pharma.
The company's model depends on the continued availability of venture funding and pharma's appetite for preclinical/clinical-stage acquisitions.

Competitive Landscape

The field of innate immune modulators is becoming increasingly competitive. For NLRP3, companies like NodThera, Ventus Therapeutics, and Inflazome (acquired by Roche) are developing antagonists. In the STING agonist/antagonist space, companies such as Merck, GSK, and numerous biotechs are active. IFM differentiates through its proven track record of rapid discovery and clinical translation, and its unique business model.

More companies in United States →